Day 2 :
Wassil Nowicky is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute, Vienna, Austria. He has completed his study at theRadiotechnical Faculty of the Technical University of Lviv, Ukraine with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. He is the inventor of the anti-cancer preparation on basis of celandine alkaloids NSC-631570.
The preparation NSC-631570 (UKRAIN) is the very first preparation against cancer with a selective effect that means that in
therapeutic dosage it kills only cancer cells leaving the healthy cells undamaged. For the invention of this preparation was used the factor that cancer cells are more negative charged than normal cells. For this purpose the Celandine alkaloid with a positive charge has been used thanks to which it accumulates in cancer cells very fast that is visible under the UV-light thanks to the auto-fluorescence. The anticancer preparation NSC-631570 has the ability to capsule cancer tumors, thanks to which the creation of new metastases is stopped. Besides, this ability makes the surgical removal of the tumors much easier. These abilities of the NSC-631570 have been confirmed by the 188 research works at 60 universities and research centers from 24 countries. To the NSC-631570 more than 300 scientific publications are dedicated and over 180 of them can be found on PubMed.
Alzahra Cancer Center Dubai, UAE
Sadir Alrawi is currently the Director of all Surgical Oncology Services at Alzahra Cancer Center in Dubai and its tertiary referral cancer center for all UAE,hosting highly specialized surgical oncology subspecialties, including colorectal, breast oncology, head &neck surgery, urology, gynecological oncology, sarcoma/melanoma and peritoneal surface malignancy, in addition topancreatic and hepatic surgery. He was the Chief of Surgical Oncology Division at Tawam Hospital andwas the Interim Chair of Department of Surgery, Tawam Hospital affiliated with John Hopkins Medical System. His major interests are gastrointestinal oncology,including esophageal, gastric, pancreas, liver and colonic surgery with special interest in endocrine surgery including thyroid, parathyroid and adrenal surgery.
Hyperbaric oxygen (HBO) therapy is the use of oxygen under elevated atmospheric pressure, that is, at a pressure higher than the pressure found on the surface of the earth at sea level, which is defined to be 1 atm. The higher pressure during hyperbaric oxygen treatment pushes more oxygen into plasma and increases the amount of oxygen bound to hemoglobin.Hyperbaric oxygen treatment has for centuries been used to improve or cure disorders involving hypoxia and ischemia, byenhancing the amount of dissolved oxygen in the plasma and thereby increasing O2 delivery to the tissue. Studies on HBO andcancer have up to recently focus on whether enhanced oxygen acts as a cancer promoter or not. As oxygen is believed to berequired for all the major processes of wound healing, one feared that the effects of HBO would be applicable to cancer tissueas well and promote cancer growth. Recent studies have shown that the hyperbaric oxygen therapy can successful as a radio sensitizer, as a chemotherapy agent, in the management of radiation induced chronic lesions and also as an adjunctive therapyto therapeutic radiation. In this paper we have summarized the results of prior studies and supplemented this with current findings. Based on the findings, there is no evidence indicating that HBO neither acts as a stimulator of tumor growth nor asan enhancer of recurrence. On the other hand, there is evidence that implies that HBO might have tumor-inhibitory effects in
certain cancer subtypes.
Al Zahra Hospital Dubai, UAE
Hosam Al-Qudah is an Uro-Oncologist and a Transplant Surgeon with special training in Laparoscopic Urology. He is currently working in Al Zahra Hospital Dubai (a tertiary referral private center) with a good number of different types of uro-oncology and laparoscopic cases.
Kidney tumors are being diagnosed in higher rates these days. Incidental finding of small renal masses is the commonest presentation. Minimal invasive management of these small masses is the slandered of care now. In this presentation, author will present an updated approach on management of these masses. The objectives are to discuss the difference betweenall available minimal invasive management of these small tumors, this will include laparoscopic partial nephrectomy and robotic partial nephrectomy; advantages of both modalities over open surgery and difference between them. We will discuss the difference between tumor enucleation versus resection and the advantage each has. Tumor ablation with different modalities is the last part of the presentation including cryosurgery, radiofrequency and other available options. Minimal invasive management of small kidney tumors is the slandered of care all around the word. These are safe and reliable methods of tumor management.